Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.
- The company has filed patent applications covering 15 novel discoveries in AI-driven voice intoxication detection.
- The platform analyzes speech patterns to estimate drug and alcohol impairment without physical samples.
- Initial commercial rollout is targeting mining and aviation via Edge AI kiosk systems, with Broader applications including call centers, law enforcement, and mental health screening.
- Technology is designed for high-volume, regulated environments where testing is costly and time consuming.
- The overall global drug and alcohol testing market is projected to reach $4.2 billion by 2033.
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection, has moved to formalize its intellectual property position in AI-driven intoxication detection, filing patent applications tied to what it describes as 15 novel discoveries in the relationship between speech patterns and the effects of neurologically active substances.
The filings, detailed in a recent company update, center on a machine learning model designed to detect drug and alcohol impairment using short voice samples. The approach departs from conventional testing methods that rely on breath, saliva, or laboratory analysis (https://ibn.fm/RQsWQ).
The company’s system evaluates more than 140 acoustic parameters and has been trained on a dataset exceeding 50 million data points. These inputs are used to identify subtle changes in speech associated with intoxication, with results delivered in near real time through standard microphones or dedicated hardware.
MindBio’s current development focus includes an Edge AI kiosk designed for enterprise deployment. The kiosk integrates both hardware and software, allowing workers or users to provide a voice sample at a fixed checkpoint, such as an industrial site entrance. According to management, delivery of the initial commercial systems remains on track for the second quarter of 2026.
“The digital health diagnostics market represents a significant opportunity for MindBio to leverage its Voice AI diagnostics technology with a first mover commercialization advantage in drug and alcohol intoxication detection,” said CEO Justin Hanka.
The commercial rationale for the technology is tied to the limitations of existing workplace testing systems. Drug and alcohol screening in regulated industries is often invasive, time consuming, and operationally disruptive, particularly in environments that require high-frequency testing across large workforces. This challenge is most visible in sectors such as mining, aviation, and construction, where safety requirements and regulatory oversight mandate routine testing. In these settings, companies must balance compliance with productivity, often at significant cost.
Market data suggests that demand for more efficient testing solutions is increasing. The global alcohol and drug testing devices market is expected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, reflecting a compound annual growth rate of around 7% (https://ibn.fm/YJ63I). Growth is being driven by stricter workplace regulations, rising awareness of substance misuse, and wider adoption of point-of-care diagnostics.
Portable and rapid-testing systems are gaining traction as employers seek to reduce reliance on centralized laboratory processes. MindBio’s voice-based model aligns with this shift, offering a non-invasive alternative that can be deployed at scale without specialized collection procedures.
The company’s initial commercial focus has been on mining operations, particularly in South America. These environments typically involve large, rotating workforces operating in remote locations, where logistical constraints can complicate traditional testing protocols.
A voice-based system could allow operators to screen workers as they enter a site, providing immediate feedback and reducing bottlenecks associated with manual or laboratory-based testing. The ability to conduct frequent, low-friction assessments is a key element of the proposed value proposition.
Beyond mining, MindBio has identified a wider set of potential use cases. Aviation and construction remain primary targets due to regulatory requirements, while law enforcement agencies may benefit from rapid, field-based screening tools. The company has also pointed to applications in call centers and mental health environments. In these settings, voice is already central to daily operations, and the ability to analyze speech for signs of impairment, fatigue, or distress could extend beyond compliance into workforce management and wellbeing monitoring.
For more information, visit the company’s website at www.MindBioTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF
